Post-Market Surveillance Under Medical Device Rules, 2017  

Regulatory approval is often treated as the finish line. In reality, for Medical Device and IVD manufacturers in India, it marks the start of an equally demanding obligation: Post-Market Surveillance (PMS). Under the Medical Device Rules, 2017, “Post-Marketing Surveillance” means a systematic process to collect and analyse information gained from Medical Devices that have been placed on the market. 

;. Manufacturers and importers are required to actively monitor device performance in the field, report adverse events, and take corrective actions when safety signals emerge. Many companies that navigate pre-market approval smoothly still stumble here — not for lack of intent, but because PMS is often under-resourced relative to its regulatory weight, treated as a compliance checkbox rather than a continuous operational function. 

What is Post-Market Surveillance (PMS)? 

After a Medical Device is approved and placed on the market, Post-Market Surveillance (PMS) monitors its continued safety, performance, and effectiveness throughout its lifecycle. This includes ongoing collection, review and analysis of real world data from the device’s actual use. 

In practical terms, PMS involves: 

• Monitoring device performance in real-world clinical and commercial settings 

• Collecting and analysing safety and performance data from multiple sources 

• Identifying risks, adverse events, or emerging patterns of concern 

• Taking corrective actions when safety signals are detected 

• Reporting findings to CDSCO in accordance with regulatory timelines 

In simple terms, it ensures that the device remains safe after it reaches patients.  

Why PMS Exists as a Distinct Obligation 

 Pre-market approval is built on data collected in controlled conditions — clinical investigations, bench testing, limited real-world exposure. Once a device reaches the open market, it encounters a larger scale and diversity of use that no pre-market study can fully replicate: diverse patient populations,  clinical settings, different levels of user training, and longer time horizons than most trials capture. PMS exists to close that gap — to catch the safety signals that only emerge once a device is actually used real time conditions.. Regulatory bodies  globally, including CDSCO, treat it not as an afterthought to approval but as an ongoing extension of the manufacturer’s responsibility to ensure device safety and performance throughout its lifecycle .

What CDSCO Requires  

The MDR 2017 vigilance framework obligates license holders to maintain a documented PMS system proportional to the risk class of the device. For higher-risk Class C and D devices, this typically means more structured, higher-frequency monitoring — periodic safety update reports, trend analysis of complaints, and proactive engagement with field data — compared to the relatively lighter obligations for Class A and B devices. In practice, this proportionality principle means a manufacturer’s PMS investment should scale with clinical risk, not with company size or resourcing convenience — a common but risky shortcut smaller manufacturers take. 

Adverse event reporting is time-bound. Serious adverse events — those resulting in death, serious deterioration of health, or a public health threat — must be reported to CDSCO and the concerned State Licensing Authority within strict timelines, generally measured in days rather than weeks. Non-serious complaints still need to be logged, trended, and reviewed periodically, since patterns across seemingly minor complaints can themselves constitute a signal that would be missed if each complaint were assessed only in isolation. Beyond individual event reporting,  

manufacturers of higher-risk devices should periodically evaluate cumulative post-market safety and performance data, including complaint trends, adverse events, benefit-risk assessments, and corrective actions, in accordance with applicable CDSCO requirements. 

. This aggregate field experience over defined intervals — not just listing adverse events, but analyzing trends, benefit-risk conclusions, and any actions taken as a result. This periodic, aggregated review is often the piece manufacturers skip, focusing energy on individual case reporting while missing the bigger picture trend analysis regulators actually want to see. 

Where Companies Fall Short 

 Several recurring gaps show up in practice, often reinforcing each other: 

 1. No formal complaint-handling SOP. Complaints arrive through multiple channels — distributors, hospitals, direct patient contact, social media in some cases — and without a centralized intake process, signals get lost before they’re ever evaluated. A complaint logged only in a distributor’s local records never reaches the manufacturer’s safety database at all.  

2. Reactive rather than proactive monitoring. PMS is treated as a reporting obligation rather than a genuine surveillance function, so trend analysis rarely happens until something has already gone wrong and a regulator or media inquiry forces a retrospective review.  

3. Disconnected quality and regulatory functions. PMS data often sits with quality teams while regulatory teams manage CDSCO correspondence — without a bridge between the two, reportable events can be missed, misclassified, or reported late, exposing the manufacturer to both safety and compliance risk simultaneously.  

4. Weak distributor and field-force training. Frontline sales and distribution staff are often the first to hear about a device issue, but if they haven’t been trained on what constitutes a reportable event and how to escalate it, valuable early signals are lost at the point of contact. 

 5. Treating PMS as a static system. A PMS SOP written once at the time of approval and never revisited quickly becomes disconnected from actual product experience, regulatory updates, and organizational changes. 

Building a Defensible PMS System 

A defensible PMS system needs several components working together, not in isolation: a documented SOP with clear escalation triggers and defined timelines at each stage; a designated PMS responsible person with real authority to make reporting decisions rather than a nominal title; integration between complaint intake and CAPA (Corrective and Preventive Action) processes so that field signals actually feed back into product and process improvement; and periodic internal audits to confirm the system is functioning as designed — not just existing on paper. Equally important is a training program that extends beyond the regulatory affairs team to sales, distribution, and customer support staff, since they are often the first point of contact when something goes wrong in the field. Manufacturers that treat PMS as a living system — reviewed, tested, and updated regularly — tend to be the ones best positioned when CDSCO scrutiny does arrive, because their documentation reflects genuine ongoing practice rather than a one-time compliance exercise. For manufacturers and importers building or auditing their PMS framework, CliniExperts supports end-to-end PMS system design, vigilance reporting, and ongoing retainer-based surveillance support to keep compliance continuous rather than reactive. 

Conclusion 

Post-Market Surveillance is not merely a regulatory obligation that begins after market approval; it is an essential component of a device’s lifecycle management. While pre-market evidence demonstrates that a device is safe and performs as intended under controlled conditions, PMS provides the real-world data needed to confirm that those expectations continue to be met once the device is used across diverse patient populations and healthcare settings. 

An effective PMS system enables manufacturers and importers to identify emerging risks early, take timely corrective and preventive actions, and maintain ongoing compliance with CDSCO requirements. More importantly, it demonstrates a continued commitment to patient safety and product quality. Organizations that invest in robust complaint handling, vigilance reporting, trend analysis, and cross-functional collaboration are better positioned to respond to regulatory scrutiny, protect their reputation, and sustain long-term market success. 

In today’s evolving regulatory environment, PMS should be viewed not as a compliance exercise, but as a strategic tool for continuous improvement, risk management, and patient protection throughout the entire lifecycle of a Medical Device.